Germline alterations among Hispanic men with prostate cancer
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
BACKGROUND: Little is known about the true rate of pathogenic (P)/likely pathogenic (LP) germline alterations in Hispanic men with prostate cancer as most studies analyzing the prevalence of P/LP germline alterations were performed in a largely non-Hispanic white population (NHW).
METHODS: We performed a retrospective analysis of two separate cohorts of men with prostate cancer: (1) a multicenter cohort of 17,256 men who underwent germline testing in a CLIA-certified laboratory and (2) a single-center cohort of all men eligible for germline testing between 2018 and 2020. The proportions of P/LP alterations and variants of uncertain significance (VUS) were computed. Fisher's exact test was used to compare germline alteration rates for significance. A multivariate logistic regression was performed adjusting for demographic and clinical factors to examine factors associated with germline testing.
RESULTS: In the multicenter cohort, the rate of P/LP germline alterations among self-reported Hispanic men was 7.1%, which was lower than self-reported NHW men (9.7% vs. 7.1%, p = 0.058), but was not statistically significant. The VUS rate was significantly higher among the Hispanic cohort (21.5% vs. 16.6%, p = 0.005). In the single-center cohort, 136 Hispanic patients were eligible for testing of which 34 underwent germline testing (26.1%, N = 34/136). Of all prostate cancer patients in the single-center cohort undergoing germline testing (n = 173), the rate of P/LP alterations in Hispanic patients was not significantly different compared to NHW patients (14.7% vs. 12.2%, p = 0.77). The rate of VUS in Hispanic patients was significantly higher than that of NHW patients (20.6% vs. 7.2%, p = 0.047).
CONCLUSION: The P/LP germline alteration rate in our cohorts was similar between Hispanic and NHW men. The rate of VUS was significantly higher in Hispanic men, a consequence of undertesting in minority populations. These data support that Hispanic men with prostate cancer should be screened for germline testing similar to NHW men.
| Errataetall: |
ErratumIn: Prostate Cancer Prostatic Dis. 2022 Apr 29;:. - PMID 35488122 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Prostate cancer and prostatic diseases - 25(2022), 3 vom: 28. Sept., Seite 561-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Elizabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.08.2022 Date Revised 21.09.2022 published: Print-Electronic ErratumIn: Prostate Cancer Prostatic Dis. 2022 Apr 29;:. - PMID 35488122 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41391-022-00517-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337600600 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337600600 | ||
| 003 | DE-627 | ||
| 005 | 20231225234806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41391-022-00517-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337600600 | ||
| 035 | |a (NLM)35228665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pan, Elizabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Germline alterations among Hispanic men with prostate cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2022 | ||
| 500 | |a Date Revised 21.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Prostate Cancer Prostatic Dis. 2022 Apr 29;:. - PMID 35488122 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a BACKGROUND: Little is known about the true rate of pathogenic (P)/likely pathogenic (LP) germline alterations in Hispanic men with prostate cancer as most studies analyzing the prevalence of P/LP germline alterations were performed in a largely non-Hispanic white population (NHW) | ||
| 520 | |a METHODS: We performed a retrospective analysis of two separate cohorts of men with prostate cancer: (1) a multicenter cohort of 17,256 men who underwent germline testing in a CLIA-certified laboratory and (2) a single-center cohort of all men eligible for germline testing between 2018 and 2020. The proportions of P/LP alterations and variants of uncertain significance (VUS) were computed. Fisher's exact test was used to compare germline alteration rates for significance. A multivariate logistic regression was performed adjusting for demographic and clinical factors to examine factors associated with germline testing | ||
| 520 | |a RESULTS: In the multicenter cohort, the rate of P/LP germline alterations among self-reported Hispanic men was 7.1%, which was lower than self-reported NHW men (9.7% vs. 7.1%, p = 0.058), but was not statistically significant. The VUS rate was significantly higher among the Hispanic cohort (21.5% vs. 16.6%, p = 0.005). In the single-center cohort, 136 Hispanic patients were eligible for testing of which 34 underwent germline testing (26.1%, N = 34/136). Of all prostate cancer patients in the single-center cohort undergoing germline testing (n = 173), the rate of P/LP alterations in Hispanic patients was not significantly different compared to NHW patients (14.7% vs. 12.2%, p = 0.77). The rate of VUS in Hispanic patients was significantly higher than that of NHW patients (20.6% vs. 7.2%, p = 0.047) | ||
| 520 | |a CONCLUSION: The P/LP germline alteration rate in our cohorts was similar between Hispanic and NHW men. The rate of VUS was significantly higher in Hispanic men, a consequence of undertesting in minority populations. These data support that Hispanic men with prostate cancer should be screened for germline testing similar to NHW men | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 700 | 1 | |a Shaya, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Madlensky, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Randall, J Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Javier-Desloges, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Millard, Frederick E |e verfasserin |4 aut | |
| 700 | 1 | |a Rose, Brent |e verfasserin |4 aut | |
| 700 | 1 | |a Parsons, J Kellogg |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Hatchell, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Esplin, Edward D |e verfasserin |4 aut | |
| 700 | 1 | |a Nussbaum, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Weise, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, James |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Maria Elena |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, Rana R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Prostate cancer and prostatic diseases |d 1997 |g 25(2022), 3 vom: 28. Sept., Seite 561-567 |w (DE-627)NLM097536202 |x 1476-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:3 |g day:28 |g month:09 |g pages:561-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41391-022-00517-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 3 |b 28 |c 09 |h 561-567 | ||